Effect of ESPB on Intraoperative Remifentanil Consumption

NCT06303557 | Completed

• 1 other identifier: AEŞH-EK1-2023-797
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

In recent years, regional anesthesia techniques have also been frequently applied to patients for pain relief. Erector spinae plane block (ESPB), is among the regional anesthesia techniques frequently used in lumbar spine surgery. General anesthesia (GA) is the main method of anesthesia for lumbar spine surgery. However, GA can only inhibit the projection system of the cortical limbic system or hypothalamic cortex. GA cannot completely block the transmission of peripheral noxious stimulus to the central nervous system and cannot effectively inhibit the intraoperative stress response. With the addition of peripheral blocks such as ESPB, lower remifentanil consumption, and more stable hemodynamics are expected by providing preemptive analgesia in patients. As a result of all these; it was aimed to compare the intraoperative remifentanil consumption of patients who underwent preoperative ESPB in patients who will undergo lumbar spine surgery resection under GA with those who underwent postoperative ESPB.

Conditions

Lumbar Spine Surgery; Erector Spinae Plane Block; Remifentanil Consumption

Outcome Measures

Primary Outcomes (1)

• Intraoperative remifentanil consumption

  The amount of remifentanil that patients need to maintain anesthesia during the intraoperative period will be recorded.

  During the intraoperative period

Secondary Outcomes (3)

• Mean arterial pressure

  Perioperative period

• Heart rate

  Perioperative period

• Pain scores

  First 24 hours after surgery

Study Arms (2)

Preoperative Erector Spinae Plane Block

ACTIVE COMPARATOR

In the preoperative period, under general anesthesia, after the linear ultrasound (US) probe will be placed 2-3 cm lateral to the L3 spinous process, 15 ml of 0.25% bupivacaine will be injected into the interfacial space below the erector spinae muscle, above the transverse process. The same ESPB procedure was performed on the other side. In total, 30 ml of 0.25% bupivacaine was administered.

Drug: Preoperative Erector Spinae Plane Block

Postoperative Erector Spinae Plane Block

ACTIVE COMPARATOR

In the postoperative period, under general anesthesia, after the linear ultrasound (US) probe will be placed 2-3 cm lateral to the L3 spinous process, 15 ml of 0.25% bupivacaine will be injected into the interfacial space below the erector spinae muscle, above the transverse process. The same ESPB procedure was performed on the other side. In total, 30 ml of 0.25% bupivacaine was administered.

Drug: Postoperative Erector Spinae Plane Block

Interventions

Preoperative Erector Spinae Plane Block DRUG

Erector spinae plane block will be performed bilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the prone position.

Preoperative Erector Spinae Plane Block

Postoperative Erector Spinae Plane Block DRUG

Erector spinae plane block will be performed unilaterally, under US guidance, after the surgical operation, under general anesthesia, and when the patient is placed in the prone position.

Postoperative Erector Spinae Plane Block

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• to 65 years old
• American Society of Anesthesiologists (ASA) physical status I-II-III
• Body mass index 18 to 30 kg/m2
• Elective lumbar disc herniation surgery

You may not qualify if:

• Patient refusing the procedure
• Patients who have previously undergone spinal surgery
• Chronic opioid or analgesic use
• Patients who will operate under emergency conditions
• Patients who will not undergo lumbar disc herniation surgery

Sponsors & Collaborators

• Atatürk Chest Diseases and Chest Surgery Training and Research Hospital: lead

Study Sites (1)

Ankara Etlik City Hospital

Yenimahalle, Ankara, 06170, Turkey (Türkiye)

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal İnvestigator

Study Record Dates

• First Submitted: February 26, 2024
• First Posted: March 12, 2024
• Study Start: January 31, 2024
• Primary Completion: November 3, 2025
• Study Completion: November 13, 2025
• Last Updated: November 26, 2025

Record last verified: 2025-11

Locations

TU (1)